Resonance Health Ltd · ASX:RHT
Resonance Health — FY2026 Earnings Presentation
35 slides from Resonance Health's earnings presentation, Aug 28, 2026
Slide 1: FY26 Full-Year Results
FY26 Full-Year Results For personal use only August 28th 2026 Andrew Harrison, CEO Benjamin Carruthers, CFO 1 1
Slide 2: In This Section: Why Resonance & FY26 Highlights
For personal use only 01 IN THIS SECTION 3 4 The Business Global Reach – Blue Chip Customers Why Resonance & 5 Why Resonance – Why Now Highlights 6 FY26 Highlights Why Resonance - Why Now & FY26 Highlights ASX : RHT 2
Slide 3: The Resonance Business
The Resonance Business For personal use only Resonance Health specialises in providing central imaging services (SaMD), contract research organisation services (CRO) and investigator site services (TrialsWest) to global pharmaceutical and biotechnology companies, hospitals and radiology centres. Cen
Slide 4: Global Reach – Blue Chip Customers
Global Reach – Blue Chip Customers For personal use only With a history in Iron measurement (“FerriScan®”) and a strong future in Metabolic disease 48 400+ 110,000+ LARGE GLOBAL REACH Countries Active sites Analyses completed BLUE-CHIP CUSTOMER BASE Map icons indicate our worldwide imaging locations
Slide 5: Why Resonance Health – Why Now
Why Resonance Health – Why Now Macro tailwinds. Three complementary businesses. All profitable. All growing. Fully aligned. For personal use only ✓ Profitable & cash-generative – today FY26 delivered: $15.8M revenue and $2.6M normalised EBITDA at a 16% margin, with positive operating cashflow in eve
Slide 6: FY26 Full-Year Highlights
FY26 Full-Year Highlights For personal use only ü Full-year revenue of $15.8M up 42% on FY25. FY23 to FY26 revenue compounded annual growth rate (CAGR) of 53%. ü Return to full-year profitability: net profit after tax of $1.5M, a $3.2M turnaround on the FY25 loss of $1.7M. ü Normalised EBITDA* of $2
Slide 7: The Three Tailwinds
For personal use only 02 IN THIS SECTION 8 The Three Tailwinds Tailwinds The macro forces driving demand — and how each business is aligned 7
Slide 8: Three Tailwinds Driving the Business
Three Tailwinds Driving the Business Three independent macro forces are converging – each accelerating demand for the exact capabilities Resonance Health has spent 20+ years building. For personal use only Liver Disease Prevalence 01 A global epidemic driving diagnostic volume 1.5B+ 20%+ 58M+ People
Slide 9: In This Section: FY26 Full Year Financial Results
For personal use only 03 IN THIS SECTION 10 11 Business Transformation Delivering Revenue Growth FY23 to FY26 12 FY26 Operating EBITDA Bridge Financial Results 13 14 Cashflow Free Cashflow Bridge 15 P&L FY25/26 FY26 Full Year Financial Results 16 Balance Sheet FY25/26 9
Slide 10: Business Transformation Delivering
For personal use only Business transformation delivering Normalised EBITDA = statutory net profit/(loss) - (R&D tax credit, FX gain) + (depreciation, amortisation & net interest expense, share based payments, and one-off restructuring & transaction * 10 costs). FY25 comparative as published includes
Slide 11: Revenue Growth – FY23 to FY26
Revenue Growth – FY23 to FY26 For personal use only ü Revenue growth across the 3 businesses ü Capturing a greater share of wallet with $3M in intercompany spending means that earnings are retained. 11
Slide 12: FY26 Normalised EBITDA Bridge
FY26 Normalised EBITDA* Bridge For personal use only Normalised EBITDA = statutory net profit/(loss) - (R&D tax credit, FX gain) + (depreciation, amortisation & net interest expense, share based payments, and * 12 one-off restructuring & transaction costs). FY25 comparative as published includes une
Slide 13: Cashflow – FY26 v FY25
Cashflow – FY26 v FY25 For personal use only Cashflow Metrics (Mill) FY26 FY25 Change $ Change % $M Normalised Operating EBITDA* 2.6 1.4 1.2 83% Cashflows from operating activities** 2.3 1.2 1.1 97% Net cash from operating activities 2.9 1.2 1.6 131% Net interest (0.2) (0.2) 0.0 (5%) Capex - Mainten
Slide 14: FY26 Free Cashflow Bridge
FY26 Free Cashflow Bridge For personal use only 1 Operating cashflow before net interest ($3.1M) = cashflows from operating activities + grants + income tax. Less net interest of $0.2M, this equals net cash from operating activities of $2.9M per 14 the Consolidated Statement of Cash Flows; less main
Slide 15: Profit & Loss – FY26 v FY25
Profit & Loss – FY26 v FY25 For personal use only ü 42% revenue growth year on year, and a return to full-year profitability with net profit after tax of $1.5M. Profit & Loss Summary1 FY26 FY25 Change $ Change % ü Normalised EBITDA margin Revenue $M 15.8 11.1 4.7 42% expanded from 13% to 16% - Norma
Slide 16: Balance Sheet – FY26 v FY25
Balance Sheet – FY26 v FY25 For personal use only Balance Sheet Summary1 $M FY26 FY25 Assets ü Cash at bank of $4.8M, up from $3.0M, with net cash of Cash and cash equivalents 4.8 3.0 $2.3M. Trade debtors and other receivables 2.5 3.5 Intangibles ü Senior secured debt reduced to $2.5M, fully drawn;
Slide 17: In This Section: The Three Businesses
For personal use only 04 IN THIS SECTION 18 19 Resonance Imaging – SaMD portfolio Resonance Clinical — MASH CRO Pipeline The Three Businesses 20 TrialsWest — Investigator Sites 21 Results by Business Segment Segment detail: sites, CRO and the SaMD endpoint portfolio 17
Slide 18: Central Imaging (SaMD) Business
Central Imaging (SaMD) Business For personal use only ü SaMD segment revenue of $7.0M1, up 34% on FY25, including services provided to Resonance Clinical trials. ü Entered new and extended clinical trial service agreements for provision of SaMD services in clinical trials (forward orders and tendere
Slide 19: Resonance Clinical (Contract Research Organisation)
Resonance Clinical (Contract Research Organisation) For personal use only ü $20.1M in total CRO contract wins since August 2023, with the balance of the major trial to be invoiced through FY27. ü $7.5M in revenue in the full year, up 81% on FY25, as the major trial moved through its delivery phase.
Slide 20: Investigator Sites
Investigator Sites For personal use only ü TrialsWest total segment revenue of $4.1M1 and external customer revenue of $2.0M in FY26 - the difference generated through trials run by Resonance Clinical. ü Second TrialsWest site at Osborne Park remains consistently profitable, with an annualised reven
Slide 21: Normalised Results by Business Segment
Normalised Results by Business Segment For personal use only Resonance Normalised SaMD TrialsWest Total ü All three segments contributed Clinical positive segment profit before Total segment revenue 7.0 7.5 4.1 18.7 group overheads in FY26. Intersegment elimination (3.0) Total group revenue 15.8 ü T
Slide 22: In This Section: Technology & Growth Strategy
For personal use only 05 IN THIS SECTION 23 24 MRI Liver Fibrosis Device & Trial Automation Platform Technology & Growth 25 Growth Path Strategy The operating leverage story, and where the next revenue comes from 22
Slide 23: Liver Fibrosis Device – Largest Single Growth Option
Liver Fibrosis Device – Largest Single Growth Option Built to address the single biggest bottleneck in MASH diagnostics and GLP-1 trial execution: non-invasive, biopsy-grade fibrosis assessment at scale. For personal use only $40B+ $23B 1.5B+ FY27/8 2026 liver disease 2026 hepatic People with chroni
Slide 24: Automation Platform – 5–10× SaMD Capacity
Automation Platform – 5–10× SaMD Capacity margin expansion The imaging business is constrained today by analyst time per job. A parallel technology programme – AI-assisted IQC, automated slice selection and a unified For personal use only modern platform – is designed to increase capacity 5–10× with
Slide 25: Growth Path – A Greater Share of Wallet
Growth Path – A Greater Share of Wallet The strategy of getting a greater “share of wallet” expands on three vectors — more therapeutic areas, more services to each customer, and more For personal use only customers — through organic (SaMD) and acquisitive (buy expertise & footprint) growth. MORE CU
Slide 26: In This Section: Capital, Risk & Investment Case
For personal use only 06 IN THIS SECTION 27 28 Capital Discipline Capital Structure & Register Capital, Risk & Investment 29 Resonance Board Case Balance sheet, register, & Board Expertise 26
Slide 27: Capital Discipline – Profitable, Cash-Generative, Self Funding
Capital Discipline – Profitable, Cash-Generative, Self Funding Macro tailwinds are being captured from a position of financial strength — the business is profitable, cash-generative, and has the operating leverage to scale For personal use only margin rapidly as revenue grows. 1 Entrenched Profitabi
Slide 28: Capital Structure & Register
Capital Structure & Register For personal use only Balance sheet, register composition and debt facility CAPITAL STRUCTURE1 REGISTER COMPOSITION2 Share price $0.067 Board & management holdings 24% Ordinary shares on issue 477,120,233 Top 20 shareholders 49% Options & performance rights 21,172,100 In
Slide 29: Board of Directors – Deep Sector Expertise
Board of Directors – Deep Sector Expertise Pharma, clinical, capital markets & commercial depth For personal use only Aaron Brinkworth Andrew Harrison Dr. David Fuller Michael Sistenich Chair Managing Director & CEO Non-Executive Director Non-Executive Director Over a 22-year career at Gilead Scienc
Slide 30: In This Section: Outlook
For personal use only 07 IN THIS SECTION 31 32 Business Outlook FY26 Guidance Delivered – FY27 Outlook Outlook The inflection to profit, and the path from $15.8M 30
Slide 31: Business Outlook
Business Outlook For personal use only FY27 priorities build on a profitable, cash-generative FY26 base ü Continued growth in SaMD volumes, supported by forward orders and pipeline exceeding $12M. ü Remaining major clinical trial milestones to be invoiced through FY27 as patients reach study complet
Slide 32: FY26 Guidance Delivered – FY27 Outlook
FY26 Guidance Delivered – FY27 Outlook For personal use only FY26 — GUIDANCE v DELIVERED FY27 — GUIDANCE Initial Guidance FY26 Delivered FY27 Guidance $M $M $M Revenue (guided $16.0M) 17 15.8 Revenue 17 to 22 Normalised EBITDA (guided $2.6M) 2 2.6 Normalised EBITDA 2.6 to 3.6 FY27 assumptions: ü In
Slide 33: Thank you – Q&A
Thank you For personal use only Q&A CONTACT Andrew Harrison — Managing Director & CEO investors.resonancehealth.com andrewh@resonancehealth.com +61 8 9286 5300 ASX : RHT Benjamin Carruthers — CFO Investor centre: investors.resonancehealth.com · LinkedIn: resonance-health-ltd 33
Slide 34: Disclaimer & Forward-Looking Statements
Disclaimer & Forward-Looking Statements For personal use only This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertaint
Slide 35: Contact Us
For personal use only Contact Us info@resonancehealth.com +61 8 9286 5300 resonancehealth.com resonance-health-ltd/ 35